Get the Stockscreener App
2.65
5.36%
-0.15
After Hours:
2.64
-0.010
-0.38%
Compugen Ltd stock is traded at $2.65, with a volume of 417.25K.
It is down -5.36% in the last 24 hours and down -14.52% over the past month.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
See More
Previous Close:
$2.80
Open:
$2.8
24h Volume:
417.25K
Relative Volume:
0.93
Market Cap:
$250.65M
Revenue:
$72.76M
Net Income/Loss:
$35.34M
P/E Ratio:
7.1757
EPS:
0.3693
Net Cash Flow:
$-62.91M
1W Performance:
-2.93%
1M Performance:
-14.52%
6M Performance:
+66.67%
1Y Performance:
+82.76%
1-Day Range:
$2.65
$2.80
1-Week Range:
$2.535
$2.92
52-Week Range:
$1.295
$3.235
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
2.65 | 264.84M | 72.76M | 35.34M | -62.91M | 0.3693 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-26 | Initiated | Lake Street | Buy |
| Jan-07-26 | Initiated | H.C. Wainwright | Buy |
| Jan-13-25 | Initiated | Oppenheimer | Outperform |
| Aug-05-22 | Downgrade | Jefferies | Buy → Hold |
| May-26-20 | Resumed | JMP Securities | Mkt Outperform |
| May-13-20 | Initiated | Stifel | Buy |
| May-07-20 | Initiated | SVB Leerink | Outperform |
| Apr-22-20 | Initiated | ROTH Capital | Buy |
| Mar-24-20 | Initiated | SunTrust | Buy |
| Jan-16-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-29-18 | Initiated | Oppenheimer | Outperform |
| Feb-01-16 | Resumed | Oppenheimer | Outperform |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Apr-23-15 | Resumed | Jefferies | Buy |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Feb-07-14 | Initiated | MLV & Co | Buy |
| Dec-28-09 | Reiterated | Cantor Fitzgerald | Buy |
| Jul-29-09 | Initiated | Cantor Fitzgerald | Buy |
View All
Compugen Ltd Stock (CGEN) Latest News
Compugen Ltd (CGEN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Investing.com Canada
Compugen Q1 2026 earnings preview - MSN
Compugen surges after revenue tops forecasts despite quarterly loss miss (CGEN) - MSN
Leerink Partners Maintains Compugen(CGEN.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
CGEN Maintains Outperform Rating -- Price Target Lowered to $5.0 - GuruFocus
H.C. Wainwright Maintains Compugen(CGEN.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Compugen Ltd. (NASDAQ:CGEN) Q1 2026 Earnings Call Transcript - Insider Monkey
Compugen (CGEN) Returns To Loss In Q1 2026 And Tests Bullish Profitability Narrative - simplywall.st
Lake Street Maintains Compugen(CGEN.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Earnings Call Summary | Compugen(CGEN.US) Q1 2026 Earnings Conference - Moomoo
CGEN: AI-driven immuno-oncology pipeline advances, with strong partnerships and extended cash runway - TradingView
Compugen Ltd at Stifel Virtual Targeted Oncology Forum Transcript - GuruFocus
Compugen: 'Buy' As Early Gastric Cancer Data Reinforces Rilvegostomig Program (NASDAQ:CGEN) - Seeking Alpha
Compugen Q1 2026 Deep Dive: EPS Misses by 14.3%, Revenue Down 5% - AlphaStreet
Compugen : Corporate Presentation - marketscreener.com
Compugen (CGEN) Reports Q1 Revenue and Long-Term Financial Stabi - GuruFocus
Compugen Files $400 Million Mixed Shelf - Moomoo
Compugen Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Compugen Ltd. (NASDAQ: CGEN) files $400M shelf; $100M ATM with Leerink - Stock Titan
Compugen Q1 2026 Earnings Call Transcript - MarketBeat
Compugen Reports Q1 2026 Financial and Clinical Progress - grafa.com
Compugen Q1 Earnings Call Highlights - MarketBeat
Earnings call transcript: Compugen’s Q1 2026 revenue beats forecast, stock rises By Investing.com - Investing.com South Africa
CGEN: Strong cash position and advancing clinical programs set the stage for key 2026–2027 milestones - TradingView
Compugen Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Compugen’s Q1 2026 revenue beats forecast, stock rises - Investing.com UK
CGEN: Solid cash position and pipeline progress set the stage for key clinical milestones in 2026 - TradingView
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Compugen Releases Q1 2026 Financial Results - AlphaStreet
Q1 2026 Compugen Ltd Earnings Call Transcript - GuruFocus
Compugen Ltd. (NASDAQ:CGEN) Q1 2026 Earnings Beat Sparks 12.73% Pre-Market Rally Amid Clinical Pipeline Progress - ChartMill
COMPUGEN ($CGEN) Releases Q1 2026 Earnings - Quiver Quantitative
Compugen earnings missed, revenue topped estimates - Investing.com India
Compugen 1Q Loss/Shr 8c >CGEN.TV - Moomoo
Compugen: Q1 Earnings Snapshot - Barchart.com
Compugen earnings missed, revenue topped estimates By Investing.com - Investing.com South Africa
Compugen Posts Q1 2026 Results, Cites Strong Cash Runway and Pipeline Advances - TipRanks
Press Release: Compugen Reports First Quarter 2026 Results - Moomoo
Compugen shares jump 18% on revenue beat despite earnings miss - Investing.com India
Compugen shares jump 18% on revenue beat despite earnings miss By Investing.com - Investing.com India
Earnings Scheduled For May 18, 2026 - Benzinga
Compugen 1Q Rev $2.18M >CGEN.TV - Moomoo
CGEN: Solid cash position and advancing clinical pipeline support operations into 2029 - TradingView
Compugen (CGEN) Q1 2026 results show cash runway to 2029 and $1B milestones - Stock Titan
Compugen cancer trials, AstraZeneca and Gilead deals, cash runway into 2029 - Stock Titan
Compugen (CGEN) Set to Release Q1 Earnings with Mixed Expectatio - GuruFocus
Compugen Ltd Stock (CGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Compugen Ltd Stock (CGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Levine Zurit | SVP, Business Development |
Apr 24 '26 |
Sale |
3.20 |
2,000 |
6,400 |
29,375 |
| Ophir Eran | President and CEO |
Apr 24 '26 |
Option Exercise |
0.83 |
5,000 |
4,146 |
16,375 |
| Ophir Eran | President and CEO |
Apr 24 '26 |
Sale |
3.20 |
5,000 |
16,000 |
11,375 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):